Forsta AP Fonden Lowers Stock Position in Gilead Sciences, Inc. $GILD

Forsta AP Fonden lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 262,000 shares of the biopharmaceutical company’s stock after selling 6,500 shares during the period. Forsta AP Fonden’s holdings in Gilead Sciences were worth $32,158,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Ares Financial Consulting LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $28,000. Financial Consulate Inc. lifted its position in shares of Gilead Sciences by 85.8% in the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 109 shares during the period. North Star Investment Management Corp. lifted its position in shares of Gilead Sciences by 54.8% in the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 86 shares during the period. MTM Investment Management LLC lifted its position in shares of Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 176 shares during the period. Finally, BOCHK Asset Management Ltd purchased a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $31,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on GILD shares. Jefferies Financial Group started coverage on shares of Gilead Sciences in a research report on Tuesday, March 10th. They issued a “buy” rating and a $180.00 price target for the company. Oppenheimer upped their price target on shares of Gilead Sciences from $128.00 to $165.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 11th. Morgan Stanley lowered their price target on shares of Gilead Sciences from $175.00 to $168.00 in a research report on Friday, May 8th. The Goldman Sachs Group upped their price target on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research report on Friday, April 17th. Finally, Weiss Ratings cut shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday. Twenty-five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $156.93.

Gilead Sciences Trading Down 1.3%

NASDAQ:GILD opened at $134.43 on Friday. Gilead Sciences, Inc. has a 52 week low of $104.46 and a 52 week high of $157.29. The firm has a 50 day moving average of $135.30 and a 200 day moving average of $134.09. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The stock has a market capitalization of $166.90 billion, a price-to-earnings ratio of 18.31 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. During the same quarter in the prior year, the company posted $1.81 earnings per share. Gilead Sciences’s revenue for the quarter was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.79 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be paid a dividend of $0.82 per share. The ex-dividend date is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. Gilead Sciences’s dividend payout ratio is presently 44.69%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the transaction, the insider owned 125,779 shares in the company, valued at approximately $16,513,524.91. This represents a 18.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the transaction, the chief executive officer owned 632,567 shares in the company, valued at $81,702,353.72. The trade was a 1.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 53,000 shares of company stock worth $7,075,670. 0.30% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.